Introduction
Pituitary adenomas account for 10-15% of diagnosed intracranial tumours (Tereda et al., 1995; reviewed in Asa and Ezzat, 1998) . Clinically, and dependent on their cellular origin, morbidity is due to hormonal excess and/ or mass effects. However, nonfunctioning pituitary tumours that account for up to 40% of pituitary adenomas lack clinical or biochemical evidence of hormonal excess. In these cases, they are frequently associated with pituitary hypofunction if residual normal tissue is damaged (Davis et al., 2001) .
For some tumour types, for example colorectal cancer, the molecular and biochemical changes responsible for tumour initiation and progression have been elucidated (Fearon and Vogelstein, 1990) . For pituitary tumours, these changes are less clearly understood (reviewed in 5), although in common with other tumour types, inappropriate growth, through deregulated homeostatic pathways, is most likely responsible for their evolution and progression. With the exception of the gsp oncogene, mutational analysis, based on candidate gene approaches, of characterized oncogenes and tumour suppressor genes (TSG) have been largely unfruitful . In contradistinction to these findings, several studies of protein and or transcript expression have described inappropriate expression of cell-cycle regulatory molecules including p16, p27, pRb, p53 and cyclin D1 (reviewed in, 5). In some cases, for example p16, pRb and death-associated protein (DAP) loss of these proteins is frequently associated with methylation of their respective CpG islands (Woloschak et al., 1997; Jaffrain-Rea et al., 1999; Simpson et al., 1999a Simpson et al., , 2000 Simpson et al., , 2002 Ruebel et al., 2001; Seemann et al., 2001) , an epigenetic mechanism of gene silencing.
Attempts to isolate novel genes implicated in pituitary tumorigenesis, and based on differential display methodologies, have led to the isolation of the pituitary tumour transforming gene (PTTG) and the growthinhibitory gene GADD45g (Pei and Melmed, 1997; Zhang et al., 2002) . Increased expression of the former (Zhang et al., 1999b) and loss of the latter (Zhang et al., 2002) is found in the majority of pituitary adenomas studied to date. The molecular mechanisms responsible for the dysregulation of these genes or their protein products are not known. Indeed, it cannot be discounted that their inappropriate expression might reflect an appropriate response to upstream or downstream factors that are themselves subject to dysregulation. GADD45g, also known as cytokine response gene 6 (CR6), is involved in growth-suppressive and apoptotic pathways (Takekawa and Saito, 1998; Wan et al., 2000) . The full-length cDNA sequences of murine (Zhang et al., 1999a) and human (Takekawa and Saito, 1998) GADD45g have been determined and the human sequence is located on the long arm of chromosome 9 (9q22.2). Analysis of the Ensembl database shows that the whole of the gene and its upstream region is embedded in a CpG island. Although inappropriate methylation of the genes CpG island has not been reported, the DAP kinase genes CpG island, telomeric to GADD45g at 9q34.1, is subject to this epigenetic change in invasive pituitary adenomas (Simpson et al., 2002) .
In this study, we determined gene-specific genetic and epigenetic aberrations that might influence GADD45g expression in sporadic human pituitary adenomas. We show that a significant proportion of adenomas fail to express GADD45g. Although loss of expression was not associated with genetic change, a significant association between loss of GADD45g expression and methylation of the genes CpG island was found. An association between methylation of GADD45g and loss of expression was also evident in a pituitary tumour cell line that in this case could be reversed by treatment with the demethylating agent 5-Aza-2 0 -deoxycytidine.
Materials and methods

Patient material
A total of 17 sporadic nonfunctional pituitary tumours (six noninvasive; 11 invasive) and 15 somatotrophinomas (12 noninvasive; three invasive), and one noninvasive prolactinoma with matched blood samples were obtained from patients who had undergone hypophysectomy. Tumour tissues were collected retrospectively after standard histological assessment and graded as previously described (Boggild et al., 1994; Bates et al., 1997; Hibberts et al., 1999) . In addition, three histologically normal post-mortem pituitaries were obtained within 12 h of death, and stored at À701C.
DNA preparation
Prior to DNA extraction, from formalin-fixed archival specimens, a single 5 mm section was subjected to H and E staining allowing tumour identification and microdissection from subsequent slides, therefore providing a microscopically homogeneous sample with minimal non-neoplastic cell contamination. DNA was extracted by prolonged (3 days) proteinase K digestion as previously described (Simpson et al., 1999b) . Supernatants were removed to fresh tubes and stored at 41C. Leucocyte DNA was extracted from matched blood samples using commercially available reagents (Nucleon 1; Nucleon, Strathclyde, Scotland).
RT-PCR analysis
Sufficient unfixed solid tumour tissue was available from 33 adenomas and three histologically normal post-mortem pituitaries for RNA extraction as previously described (Chomczynski and Sacchi, 1987) . A total of 2-5 mg of total RNA was heated to 701C for 10 min in the presence of 0.25 mg random hexamer oligonucleotides, and then snap cooled on ice in a total volume of 12 ml. In a final volume of 20 ml, the reaction contained 200 mM of dATP, dGTP, dTTP, and dCTP, 1 Â first-strand buffer mix (GibcoBRL, Life Technologies Ltd, UK), 10 mM dithiothreitol. The reaction was heated at 421C for 2 min prior to the addition of 2 U of reverse transcriptase (Superscript II Rnase H-Reverse Transcriptase; GibcoBRL, Life Technologies Ltd, UK). The reaction mix was incubated for a further 1 h at 421C. The reaction was stopped by heating to 951C for 5 min, and cDNAs stored at À201C. PCR amplification of the resulting cDNA was achieved with oligonucleotides specific for the GADD45g gene, designed according to the published sequence (Ensemble Gene ID #00000130222). PCR amplification was limited to 30 cycles to ensure amplification in the exponential phase. To confirm cDNA integrity, a portion of the housekeeping gene HPRT was co-amplified in a duplex reaction from tumour and histologically normal post-mortem pituitary. Oligonucleotide sequences are shown in Table 1 . Reactions were hot started (961C for 5 min) and PCR amplification conditions were 30 cycles, (601C for 30 s, 721C for 30 s and 941C for 1 min). PCR and product visualization were carried out as described for LOH.
LOH analysis
Oligonucleotide sequences to two highly polymorphic microsatellite markers located on 9q22.2 (D9S283 and D9S1815) were used, and their location and sequence were obtained from the Genome DataBase (Table 1) . Approximately 200 ng of patient-matched blood and tumour DNA were PCR amplified for these microsatellite markers in 25 ml volumes with 1.5 mM MgCl 2 , 200 mM each of dATP, dGTP, dTTP and dCTP, 20 pmol of each primer, and 1 U Taq DNA polymerase. PCR was carried out for 25-28 cycles at an annealing temperature of 551C for the marker D9S1815 and at 501C for the marker D9S283 (55 or 501C for 30 s, 721C for 30 s and 941C for 1 min). Products were run on 8% nondenaturing polyacrylamide gels, fixed in 10% methylated spirit/0.5% acetic acid for 6 min and then incubated in 0.1% aqueous silver nitrate for 15 min. Following two brief washes in distilled water, products were visualized by development in 1.5% sodium hydroxide/0.1% formaldehyde.
Loss of heterozygosity was identified in patient tumour DNA by a reduction in allele intensity of greater than 80% (as assessed by scanning densitometry), or by the absence of one of the expected PCR products in the amplified tumour DNA. Leucocyte and tumour template DNA was serially diluted prior to PCR amplification and the dilutions were compared with those producing similar band intensities between constitutional DNA and the remaining allele(s) in the matched tumour sample. Leucocyte DNA that, after PCR amplification, did not show distinguishable paternal and maternal alleles was deemed noninformative. LOH was confirmed after three repeat analyses. In all cases, the frequency of loss at individual microsatellite markers represents only informative tumours and excludes patients in which tumour and/or matched bloods failed to amplify (see Results).
Sequence analysis of GADD45g
The four coding exons of GADD45g were sequenced from post-mortem pituitaries and those tumours that failed to express this transcript but were not methylated (see Results). Intronic primers were designed to encompass each of the first three exons. For exon 4, two overlapping amplicons were generated that included the exon-intron boundaries. Primer sequences are shown in Table 1 together with product size postamplification. The individual exons were subjected to PCR amplification using the gene-specific oligonucleotides and conditions as described above (annealing temperatures 55-601C). PCR amplicons were subjected to cycle sequencing reactions according to the manufacturer's protocol (BigDyet Terminator cycle sequencing, PE Applied Biosystems, Warrington, UK) using both sense and antisense PCR oligonucleotides. Cycle sequencing products were subjected to capillary electrophoresis using an automatic sequencer (ABI Prism 310 Genetic Analyser, PE Applied Biosystems, Warrington, UK). Sequencing data were analysed using Sequencing Analysis V3.0 (ABI Prism, PE Applied Biosystems, Warrington, UK).
Sodium bisulphite modification
DNA (0.5-1.0 mg) was denatured with NaOH (final concentration 0.2 M) in a total volume of 10 ml for 10 min at 371C. Salmon sperm DNA (1 mg) was added as a carrier prior to denaturation. Sodium bisulphite solution (250 ml; 0.5 M hydroquinone, 2.2 M sodium bisulphite) at pH 5, freshly prepared, was added and mixed. To ensure full denaturation and deamination, DNA samples were denatured at 951C for 5 min and further incubated at 551C for 4 h (Grigg, 1996) . DNA samples were then purified using the Wizard purification resin according to the manufacturer's protocol (Promega, UK) and eluted in 50 ml of water. The modification was completed by desulphonation with NaOH (final concentration 0.3 M) for 15 min at 371C. DNA was ethanol precipitated and resuspended in 10 ml of water. Samples were stored at À201C.
Sodium bisulphite sequencing of the GADD45g genes CpG island
Primers were designed to recognize sodium bisulphite converted DNA and encompassing a total of 23 CpG dinucleotides within the human GADD45g genes CpG island (nts À200 to þ 50 relative to the transcription start site). Primer sequences are shown in Table 1 . PCR reactions contained primer sets specific for converted DNA (2 pmol of each primer), 1.5 mM MgCl 2 and 200 ng of modified template DNA. Reactions were hot started (961C for 5 min) before the addition of 1 U Taq DNA polymerase and 200 mM each of dATP, dGTP, dTTP and dCTP. The PCR was carried out for 30 cycles (521C for 30 s, 721C for 30 s and 941C for 1 min). A measure of 1 ml of the primary amplification was subject to a hemi-nested secondary PCR amplification using an internal reverse primer (Table 1) under conditions identical to those described for the primary amplification. Post-PCR amplification products were subject to TA cloning using conditions Table 1 Sodium bisulphite DNA sequencing: Oligonucleotides that are specific for a region of the GADD45g gene CpG island in human (h) (Ensemble Gene ID #00000130222) and mouse (m) (Ensemble Gene ID #00000021453) following sodium bisulphite modification. MS-PCR: Oligonucleotide sequence that are specific for methylated (GADD45 M) and unmethylated (GADD45U) GADD45g genes CpG islands DNA following sodium bisulphite modification. RT-PCR analysis: Oligonucleotide sequences specific for human and mouse GADD45g (hGADD45-RT) and (mGADD45-RT), respectively. Human HPRT (hHPRT-RT) and mouse PBGD (mPBGD) cDNA-specific primers are also shown (HPRT GenBank accession no. M26434, PBGD accession 00000032126). GADD45g sequence analysis: Oligonucleotides specific for the GADD45g exons 1-4 are shown. EX, denotes exons. Primer sets (i) and (ii) generate overlapping amplicons of exon 4 together with 5 0 and 3 0 intronic sequences, respectively. Microsatellite analysis: Oligonucleotides specific for the microsateillite D9S283 and D9S1815 (GenBank accession no. Z24343 and Z52921, respectively) Name Forward primer Reverse primer Size (bp)
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Loss of expression of growth inhibitory gene A Bahar et al recommended by the manufacturer (Promega, UK). Individual molecules were then subject to sequence analysis as described above.
Methylation of GADD45g by methylation-sensitive PCR
Oligonucleotide sets were designed according to the criteria previously described (Herman et al., 1996) . Oligonucleotide sequences were designed to a region of the GADD45g CpG island found to be frequently methylated by methylationsensitive sequencing (see above and Results). In addition, the oligonucleotides were designed to regions containing frequent cytosines (to distinguish between modified and unmodified DNA) and contained CpG dinucleotides at the 3 0 end (to provide maximal discrimination between methylated and unmethylated DNA). Oligonucleotide sequences are shown in Table 1 . As a positive control, for efficient sodium bisulphite modification, we methylated genomic DNA in vitro with the CpG methylase enzyme SssI. This DNA was then subjected to sodium bisulphite modification as described above and included in the methylation-sensitive PCR (MS-PCR).
Treatment with 5-Aza-2 0 -deoxycytidine
The pituitary corticotroph tumour cell line AtT20 was cultured as previously described (Frost et al., 1999) . For the demethylation studies, cells were exposed continuously to 5-Aza-2 0 -deoxycytidine (1 mM) for 5 days. Mock-treated cells were treated with an equivalent volume of vehicle (PBS) alone. Cells were cultured for a further 7 days in the absence of drug prior to DNA and RNA extraction. Sodium bisulphite sequencing and RT-PCR analysis was carried out as described above and primer sequences are shown in Table 1 . As control for methylation and expression status, we used normal mouse pituitaries as described previously (Frost et al., 1999) .
Statistical analysis w
2 and Fisher's exact test analyses were performed to determine the relationship between expression status and/or methylation status, and clinicopathological features (tumour grade and subtype) were obtained using a Stata statistical package (version 5, Stata Corp, TX, USA). Significance was taken at the 5% level.
Results
GADD45g expression status in sporadic pituitary adenomas
We determined GADD45g mRNA expression status by RT-PCR analysis in 33 human pituitary tumours and in post-mortem normal pituitaries. Figure 1 shows the presence of a GADD45g transcript in post-mortem normal pituitaries and in 11 of 33 (33%) adenomas. However, we failed to detect expression in 22 of 33 adenomas (67%). The presence of the larger HPRT amplicon by duplex PCR confirmed cDNA integrity in all of the samples examined (Figure 1 and summarized in Table 2 ).
Loss of heterozygosity analysis
A possible cause for loss of GADD45g in pituitary adenomas included loss of heterozygosity (LOH) or homozygous deletion. To examine these possibilities, two microsatellite markers that map to 9q22.2 (D9S283 and D9S1815) were employed. Analysis of tumourmatched blood DNA samples showed 32 of 33 specimens to be informative for the marker D9S283 and 27 of 33 for D9S1815. None of the adenomas, with either marker, showed reduction to hemizygosity (Table 2) . Since there are no characterized intragenic polymorphic microsatellites within the GADD45g gene, we were unable to rule out the possibility of intragenic deletion.
Epigenetic aberrations of the GADD45g gene
GADD45g has a CpG island that maps to its presumed 5 0 -promoter region and extends to cover all the coding sequence and intervening introns. Since several studies have described methylation-associated gene silencing in pituitary adenomas (Woloschak et al., 1997; JaffrainRea et al., 1999; Simpson et al., 1999a Simpson et al., , 2000 Simpson et al., , 2002 Ruebel et al., 2001; Seemann et al., 2001) , we examined the methylation status of 23 CpG dinucleotides within the 5 0 region and extending into the coding sequence of GADD45g. We first used sodium bisulphite sequencing of DNA from post-mortem normal pituitaries and three adenomas in which the expression status of GADD45g had been determined. Figure 2 shows the methylation status of individual molecules from each of these specimens. There was a complete absence of methylation in the post-mortem normal pituitary specimen and in the adenoma that expressed GADD45g transcript. In the two tumours that failed to express this transcript, one (no. 145) was completely methylated across individual CpG dinucleotides and on all individual molecules. In the second adenoma (no. 515), four of five molecules were completely methylated and one was not (Figure 2 and summarized in Table 2 ).
Assessment of methylation status of GADD45g by MS-PCR
Based on the data derived from sodium bisulphite sequencing, we designed MS-PCR primers that recognized the methylation status of CpG dinucleotides within the CpG island of GADD45g. The forward primer recognized CpG dinucleotides 16 and 17 upstream of the transcription start site (see Figure 2) , and the reverse primer CpG dinucleotides within the first coding exon. The two sets of primers are designed to take advantage of nucleotide differences as a result of sodium bisulphite conversion and recognize either unmethylated (GADD45U) or methylated sequence (GADD45M). In all, nineteen of 33 adenomas (58%) were methylated, and examples are shown in Figure 3 and summarized in Table 2 . Fourteen of 33 (42%) adenomas were unmethylated as were the post-mortem normal pituitaries ( Figure 3, Table 2 ). A single adenoma (no. 515) showed an amplicon with primers specific for both a methylated and unmethylated CpG island confirming the status assigned by methylation-sensitive sequencing (see above). Control DNA shown by sodium bisulphite sequencing to be unmethylated and subject to Loss of expression of growth inhibitory gene A Bahar et al in vitro methylation (IVM) gave a positive signal with primers designed to recognize methylated CpG dinucleotides. Conversely, we failed to generate an amplicon with primers that recognize an unmethylated CpG island in this sample.
Association between GADD45g methylation status and expression
Of 22 adenomas that failed to express GADD45g transcript by RT-PCR analysis, 18 (82%) were methylated by MS-PCR analysis and/or sodium bisulphite sequencing. Of 11 adenomas that expressed GADD45g transcript, 10 (91%) were not methylated and all postmortem pituitaries that expressed GADD45g were unmethylated. However, at low frequency the association between methylation status and expression did not hold true, in that four of 22 (18%) adenomas that failed to express GADD45g were not methylated as determined MS-PCR analysis and also confirmed by methylationsensitive sequencing. Conversely, one of 11 (9%) adenomas that did express GADD45g was methylated. The association between methylation and loss of expression was statistically significant (P ¼ 0.002). No association was found between methylation or expression status and tumour subtype or grade. Data are summarized in Table 2 .
GADD45g mutation analysis
In the four adenomas that failed to express GADD45g, but were not methylated, we sequenced all the coding 
Re-expression studies
Since human pituitary tumours do not proliferate in culture, we used the characterized mouse pituitary cell line AtT20 for re-expression studies. Sodium bisulphite sequencing of a portion of the GADD45g genes CpG island showed an absence of methylation in normal mouse pituitary, but dense methylation in AtT20 cells (Figure 4) . By RT-PCR analysis, we failed to detect GADD45g transcript expression in AtT20 cells; however, this transcript was readily detected in normal mouse pituitary (Figure 4 ). Post-drug treatment robust reexpression of GADD45g was detected in AtT20 cells.
Discussion
In a recent study, Zhang and co-workers employing cDNA-representational difference analysis (cDNA-RDA) isolated and identified GADD45g as underrepresented in pituitary adenomas (Zhang et al., 2002) . By RT-PCR analysis, they showed that GADD45g is not expressed in the majority of functional and nonfunctional pituitary adenomas. In the present study, we examined the expression of GADD45g in sporadic pituitary adenomas and searched for genetic and epigenetic alterations that might be responsible for or associated with loss of expression. We reached a conclusion similar to the single previous report (Zhang et al., 2002) , and found that the majority of adenomas (67%) investigated failed to express GADD45g as assessed by RT-PCR analysis. Several lines of evidence, including sodium bisulphite sequencing and MS-PCR showed that in the majority of cases, where GADD45g was not expressed, that loss was associated with methylation of the genes CpG. With the exception of this epigenetic change, we did not detect genetic alteration, as determined by either LOH or direct sequence analysis within the coding region of the GADD45g gene. GADD45g (CR6) belongs to a family of genes that includes GADD45a (GADD45) and GADD45b (MyD118), which serve similar but not identical functions along different apoptotic and growth-suppressive pathways (Fornace et al., 1998; Takekawa and Saito, 1998; Zhang et al., 1999a) . However, the protein products of these genes have all been shown to interact with and activate the MTK1/JNK/p38 stress cascade (Azam et al., 2001 and references therein). More recently, GADD45g has, in common with the other family members, been shown to interact with PCNA and p21 (Azam et al., 2001) . Consistent with a role for GADD45g in negative growth regulation, Zhang and colleagues (Zhang et al., 2002) showed that transfection of GADD45g cDNA, in pituitary-derived cell lines, resulted in a substantial growth reduction in colonyforming assays. Similar findings in the lung cancer cell line H1299 have been reported, where expression resulted in retardation of cell proliferation and G1 arrest . These latter studies also showed that expression of these proteins sensitized cells to apoptosis induced by genotoxic stress. Collectively, these data would support a central role for members of the GADD45 family in the maintenance of normal cellular homeostasis and conversely where loss may lead to dysregulated growth.
In addition to pituitary tumours, loss of GADD45g expression has also been reported at a high frequency in oral melanomas (Korabiowska et al., 1999) . However, to our knowledge, mechanisms responsible for loss have not been reported. We initially looked for LOH or homozygous deletion with microsatellite markers to 9q22.2, reasoning that LOH might be accompanied by mutation in the retained allele in fulfilment of Knudsen's two-hit hypothesis (Knudson, 1996) , or where homozygous deletion could account for loss of GADD45g. We failed to detect homozygous deletion or LOH, suggesting that these were not likely mechanisms responsible for loss of transcript expression.
Epigenetic mechanisms associated with gene silencing, namely methylation of CpG islands, are one of the most frequent findings in cancer (for a review see Baylin et al., 1998) . Inappropriate methylation targets multiple genes, including those responsible for cell cycle regulation, DNA repair, drug resistance and detoxification, differentiation, apoptosis, angiogenesis, metastasis and invasion (reviewed in Baylin et al., 1998) . For pituitary tumours, several studies now show highly frequent methylation of the p16 gene (Woloschak et al., 1997; Jaffrain-Rea et al., 1999; Simpson et al., 1999a; Ruebel et al., 2001; Seemann et al., 2001) , and where investigated show significant associations with loss of p16 protein. Our own studies showed pituitary tumour, subtype-specific, CpG island methylation of p16 and RB1, associated with a loss of cognate protein, in nonfunctioning pituitary tumours and somatotrophinomas, respectively (Simpson et al., 1999a (Simpson et al., , 2000 . In the present study, we found a highly significant correlation However, in tumours no. 145, no. 149, no. 436, no. 482 and no. 515, we were unable to detect GADD45g expression. The amplification of HPRT confirmed the integrity of individual cDNA samples in each case Loss of expression of growth inhibitory gene A Bahar et al between methylation of the GADD45g genes CpG island and absence of gene expression that was not associated with tumour subtype or growth characteristics.
In an attempt to establish a mechanistic link between methylation and gene silencing, we used the mouse pituitary cell line AtT20. These studies showed that methylation-associated silencing of GADD45g could be reversed by treatment with the demethylating agent 5-Aza-2 0 -deoxycytidine. Other investigators have reported similar findings, for other methylated genes, in different tumour types thereby establishing the functional significance of methylation in gene silencing (reviewed in Baylin et al., 1998) . Collectively, these findings would support a functional link between methylation and gene silencing; however, recent reviews have suggested that methylation might simply reinforce a pre-established gene silencing event imposed by other, as yet unidentified, mechanisms (Clark and Melik, 2002; Turker, 2002) . However, the fact that demethylation results in reactivation of a silenced GADD45g gene in these cells indicates that methylation is at least partially responsible for loss of gene transcription.
Although we, and a single previous first report (Zhang et al., 2002) , now show loss of GADD45g to occur at high frequency in pituitary adenomas, a direct causal role in pituitary tumour evolution has not been established. In this context, the generation of GADD45g null mice will be important in addressing this question. Indeed, it could be argued that methylation-mediated gene silencing of GADD45g is simply a consequence of dysregulation in pathways that regulate maintenance and/or de novo methylation activity in these cells, and perhaps targets multiple genes irrespective of their function. We feel this is not the case for several reasons. First, in a recent report we showed, in a single cohort of pituitary adenomas, mutually exclusive methylation of p16 and RB1 in nonfunctioning adenomas and somatotrophinomas, respectively (Simpson et al., 2001) . Second, and perhaps more compelling, we have also shown methylation of the DAP kinase genes CpG island, which is a significant association with invasive pituitary tumours in comparison to their noninvasive counterparts (Simpson et al., 2002) . Interestingly, the DAP kinase gene maps telomeric to GADD45g at 9q34.1. However, in the present investigation although loss and methylation of GADD45g were independent of tumour Figure 3 Representative examples of MS-PCR analysis of the GADD45g genes CpG island in pituitary tumours and normal postmortem pituitaries. DNA samples were sodium bisulphite treated prior to MS-PCR analysis. Modified DNA samples were subjected to PCR analysis with oligonucleotides specific for unmethylated (U) or methylated (M) DNA. A PCR product is generated from in vitro methylated genomic DNA (IVM), with the oligonucleotide set specific for methylated but not unmethylated DNA. The absence of methylation in histologically normal post-mortem pituitaries is demonstrated by the presence of a PCR product generated by the oligonucleotides specific for unmethylated DNA. Representative PCR products corresponding to methylated (no. 145, no. 149, and no. 515) and unmethylated (no. 439 and no. 408) tumours are also shown. In some cases (no. 515), a PCR product was generated representing both an unmethylated and methylated CpG island. No methylation was found in any of the matched blood DNA samples examined (data not shown). Patient numbers are shown above each lane. An amplicon in the lanes denoted U represents amplification from unmethylated DNA and methylated DNA in the lanes denoted M, post-sodium bisulphite conversion subtype or growth characteristics, this was not the case for the DAP kinase gene CpG island, suggesting that these epigenetic changes do not represent random methylation errors. Finally in other tumour types, investigators have examined multiple CpG islands that are commonly methylated in cancer (Huang et al., 1999; Yan et al., 2000; Esteller et al., 2001) . Collectively, these studies show common methylated CpG islands across different tumour types, others that show tumour-type specificity and still others where the methylation signature correlates with clinical parameters. Taken together, these findings would argue against CpG island methylation simply reflecting dysregulation of methylase activity within tumour cells.
In summary, we find that GADD45g expression is lost in the majority of human pituitary adenomas investigated. Loss of this transcript is not associated with genetic abnormalities. However, methylation of the GADD45g genes CpG island was found at high frequency in those tumours where expression of this gene was compromised. Furthermore, a functional association between loss of expression and methylation was established through drug-induced demethylation and subsequent re-expression in AtT20 cells. Since the gene is present in these tumours, but is rendered transcriptionally incompetent, it is a favourable target for pharmacological interventions designed to reverse these changes and thus restore expression. In addition, the differential methylation of particular genes in tumours with different growth characteristics may provide useful data for the design and application of treatment modalities.
